Cliff Asness AQR Capital Management
Cliff Asness is a co-founder of AQR Capital Management, a leading quantitative investment firm spanning equities, alternatives, and factor strategies. He is known for academic-informed research on value, momentum, and other systematic premia, as well as candid market commentary. Asness’s work bridges academic finance and large-scale institutional portfolio management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.58% |
| 2 | Healthcare | 16.26% |
| 3 | Financials | 11.97% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1651
iShares MSCI India ETF
INDA
$6.59B
| $760K | ﹤0.01% |
18,209
| – | – |
|
1652
Telos
TLS
$327M
| $760K | ﹤0.01% |
+149,285
| New | +$988K |
|
1653
Q2 Holdings
QTWO
$4B
| $757K | ﹤0.01% |
28,157
+11,241
| +66% | +$314K |
|
1654
First Solar
FSLR
$22.4B
| $752K | ﹤0.01% |
5,122
+3,089
| +152% | +$458K |
|
|
DOOR
1655
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
| $751K | ﹤0.01% |
9,311
-3,690
| -28% | -$273K |
|
|
AKRO
1656
DELISTED
Akero Therapeutics
AKRO
| $750K | ﹤0.01% |
+13,683
| New | +$586K |
|
|
LL
1657
DELISTED
LL Flooring Holdings, Inc.
LL
| $747K | ﹤0.01% |
132,852
+89,336
| +205% | +$626K |
|
1658
Tilly's
TLYS
$114M
| $746K | ﹤0.01% |
82,450
-201,405
| -71% | -$1.77M |
|
1659
FIGS
FIGS
$2.53B
| $746K | ﹤0.01% |
110,822
+69,403
| +168% | +$499K |
|
|
SNBR
1660
DELISTED
Sleep Number
SNBR
| $746K | ﹤0.01% |
28,697
+22,533
| +366% | +$684K |
|
1661
TaskUs
TASK
$718M
| $745K | ﹤0.01% |
+44,109
| New | +$829K |
|
1662
PJT Partners
PJT
$4.51B
| $744K | ﹤0.01% |
10,095
-225
| -2% | -$16.9K |
|
|
FIRY
1663
Firy Inc
FIRY
$151M
| $744K | ﹤0.01% |
74,239
+72,224
| +3,584% | +$1.33M |
|
|
CFB
1664
DELISTED
CrossFirst Bankshares, Inc. Common Stock
CFB
| $739K | ﹤0.01% |
59,543
+479
| +0.8% | +$6.37K |
|
1665
Arbor Realty Trust
ABR
$979M
| $738K | ﹤0.01% |
55,986
+22
| +0% | +$299 |
|
|
GTLS
1666
DELISTED
Chart Industries
GTLS
| $738K | ﹤0.01% |
6,479
+1,038
| +19% | +$167K |
|
1667
NACCO Industries
NC
$309M
| $737K | ﹤0.01% |
19,383
-12,351
| -39% | -$581K |
|
1668
APi Group
APG
$17.6B
| $736K | ﹤0.01% |
58,689
-24,923
| -30% | -$288K |
|
1669
Casella Waste Systems
CWST
$6.03B
| $734K | ﹤0.01% |
9,256
+206
| +2% | +$16.5K |
|
1670
CNB Financial Corp
CCNE
$1.01B
| $733K | ﹤0.01% |
+30,819
| New | +$763K |
|
|
MNTV
1671
DELISTED
Momentive Global Inc. Common Stock
MNTV
| $732K | ﹤0.01% |
104,567
-79,896
| -43% | -$576K |
|
1672
Funko
FNKO
$385M
| $732K | ﹤0.01% |
67,058
+33,966
| +103% | +$477K |
|
1673
Ultragenyx Pharmaceutical
RARE
$2.54B
| $729K | ﹤0.01% |
15,914
+5,692
| +56% | +$224K |
|
1674
Teekay Tankers
TNK
$3.19B
| $727K | ﹤0.01% |
23,584
+11,347
| +93% | +$361K |
|
1675
Universal Corp
UVV
$1.14B
| $726K | ﹤0.01% |
13,749
+917
| +7% | +$47.7K |
|
Similar funds
Cliff Asness's Q4 2022 Portfolio in Review
As of Q4 2022, Cliff Asness held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Cliff Asness's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- Cliff Asness's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- Cliff Asness added most to Humana in Q4 2022, an estimated $111M increase.
- Cliff Asness's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- Cliff Asness fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- Cliff Asness's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- Cliff Asness opened 170 new positions and closed 150 in Q4 2022.
- Cliff Asness's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.